Rani Therapeutics reports Q3 EPS (12c), consensus (12c)

Cash, cash equivalents and marketable securities as of September 30 totaled $4.1M, compared to $27.6M for the year ended December 31, 2024. Rani expects its cash, and cash equivalents, including the additional funds from the private placement closed in October and the initial upfront payment and expected technology transfer milestone from the agreement with Chugai, to be sufficient to fund its operations into 2028. “We are proud to begin a new chapter for Rani, with world-class pharma partners and top-tier biotech investors demonstrating confidence in our platform and vision to transform injectable biologics into oral therapies,” said Talat Imran, CEO. “Our collaboration with Chugai, which could reach a total value of over $1B, together with the oversubscribed $60.3M private placement, provides validation of the transformative potential of our RaniPill platform. With our cash runway expected to extend into 2028 and Abraham Bassan and Vasudev Bailey, Ph.D. joining our board of directors, we are well-positioned to execute on our strategy as we enter a new era of growth. Looking ahead, we remain focused on initiating a Phase 1 trial for RT-114, our novel oral therapy targeting obesity, by the end of 2025.”